Pershing Edward bought PVCT
February 15, 2025 · Form 4 insider transaction
Pershing Edward bought 27,989 shares of Provectus Biopharmaceuticals, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
27,989
Price
$0.00
Total value
N/A
InsiderPershing Edward
Role—
SecuritySeries D-1 Convertible Preferred Stock
Transaction codeM: Option exercise
Transaction dateFebruary 15, 2025
Filing dateFebruary 19, 2025
Shares owned after1,827,623
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").; The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.